Intellia Therapeutics Inc NTLA

Healthcare Biotechnology

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

NDAQ:NTLA - Post by User

Intellia Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Oct 12, 2024 6:15pm

56 Views

Post# 36264162

When (NTLA) Moves Investors should Listen

JUST IN: $NTLA When (NTLA) Moves Investors should Listen2024-10-12 17:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...NTLA - When (NTLA) Moves Investors should Listen

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario